NCT03308084

Brief Summary

The purpose of this study is to determine if the frequency and duration of postoperative pain are improved in participants receiving a local steroid injection (methylprednisolone) plus a systemic (intravenous (IV, by vein)) steroid (dexamethasone) when compared to those receiving a systemic (IV) steroid (dexamethasone) alone. Both of these steroid injections are already currently used at Rush and are considered standard of practice. It is well established that steroids have an anti-inflammatory (decreased swelling) effect on the soft tissue and it is routinely used in many types of surgery, but it is not known whether two steroids are better than one. The medications provided in this study are approved by the Food and Drug Administration (FDA).

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
105

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Nov 2015

Typical duration for phase_3

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 13, 2015

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

October 5, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 12, 2017

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 3, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 3, 2019

Completed
Last Updated

November 20, 2020

Status Verified

November 1, 2020

Enrollment Period

3.5 years

First QC Date

October 5, 2017

Last Update Submit

November 18, 2020

Conditions

Keywords

transforaminal lumbar interbody fusion, methylprednisolone

Outcome Measures

Primary Outcomes (1)

  • Postoperative Pain

    Change in Visual Analogue Scale Back and Leg score from preoperative value will be assessed

    2 years postoperative

Secondary Outcomes (7)

  • Physical Functioning

    2 years postoperative

  • Disability

    2 years postoperative

  • General health status

    2 years postoperative

  • Narcotic Consumption

    1 week postoperative

  • Length of Stay

    1 week postoperative

  • +2 more secondary outcomes

Study Arms (2)

Local Depomedrol plus IV dexamethasone

ACTIVE COMPARATOR

Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone

Drug: MethylprednisoloneDrug: Dexamethasone

IV dexamethasone

PLACEBO COMPARATOR

Standard systemic (IV) dexamethasone only

Drug: Dexamethasone

Interventions

Application of 80mg Depomedrol (methylprednisolone acetate) suspension into the transforaminal space prior to incision closure

Local Depomedrol plus IV dexamethasone

Administration of 10mg Dexamethasone IV intraoperatively

IV dexamethasoneLocal Depomedrol plus IV dexamethasone

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing a primary 1- to 2-level MIS TLIF
  • Diagnosis: myelopathy, radiculopathy, myeloradiculopathy, stenosis, herniated nucleus pulposus, degenerative disc disease, spondylosis, osteophytic complexes, and foraminal stenosis
  • Patients able to provide informed consent

You may not qualify if:

  • Allergies or other contraindications to medicines in the protocol including:
  • (a) Existing history of gastrointestinal bleeding
  • Current Smokers
  • Lumbar spine trauma
  • Bilateral cages
  • Lack of consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (6)

  • Schizas C, Tzinieris N, Tsiridis E, Kosmopoulos V. Minimally invasive versus open transforaminal lumbar interbody fusion: evaluating initial experience. Int Orthop. 2009 Dec;33(6):1683-8. doi: 10.1007/s00264-008-0687-8. Epub 2008 Nov 21.

    PMID: 19023571BACKGROUND
  • McGirt MJ, Parker SL, Lerner J, Engelhart L, Knight T, Wang MY. Comparative analysis of perioperative surgical site infection after minimally invasive versus open posterior/transforaminal lumbar interbody fusion: analysis of hospital billing and discharge data from 5170 patients. J Neurosurg Spine. 2011 Jun;14(6):771-8. doi: 10.3171/2011.1.SPINE10571. Epub 2011 Mar 18.

    PMID: 21417699BACKGROUND
  • Ranguis SC, Li D, Webster AC. Perioperative epidural steroids for lumbar spine surgery in degenerative spinal disease. A review. J Neurosurg Spine. 2010 Dec;13(6):745-57. doi: 10.3171/2010.6.SPINE09796.

    PMID: 21121754BACKGROUND
  • Jamjoom BA, Jamjoom AB. Efficacy of intraoperative epidural steroids in lumbar discectomy: a systematic review. BMC Musculoskelet Disord. 2014 May 5;15:146. doi: 10.1186/1471-2474-15-146.

    PMID: 24885519BACKGROUND
  • Debi R, Halperin N, Mirovsky Y. Local application of steroids following lumbar discectomy. J Spinal Disord Tech. 2002 Aug;15(4):273-6. doi: 10.1097/00024720-200208000-00002.

    PMID: 12177541BACKGROUND
  • Haws BE, Khechen B, Patel DV, Bawa MS, Ahn J, Bohl DD, Mayo BC, Massel DH, Guntin JA, Cardinal KL, Singh K. Impact of local steroid application in a minimally invasive transforaminal lumbar interbody fusion: results of a prospective, randomized, single-blind trial. J Neurosurg Spine. 2018 Nov 9;30(2):222-227. doi: 10.3171/2018.7.SPINE18584. Print 2019 Feb 1.

MeSH Terms

Conditions

Aphasia

Interventions

MethylprednisoloneDexamethasone

Condition Hierarchy (Ancestors)

Speech DisordersLanguage DisordersCommunication DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PrednisolonePregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, Fluorinated

Study Officials

  • Kern Singh, MD

    Rush University Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, Department of Orthopaedic Surgery

Study Record Dates

First Submitted

October 5, 2017

First Posted

October 12, 2017

Study Start

November 13, 2015

Primary Completion

May 3, 2019

Study Completion

May 3, 2019

Last Updated

November 20, 2020

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will not share